HUE026334T2 - ATP-kötõ kazetta (ABC) transzporterek izokinolin modulátorai - Google Patents

ATP-kötõ kazetta (ABC) transzporterek izokinolin modulátorai Download PDF

Info

Publication number
HUE026334T2
HUE026334T2 HUE12181370A HUE12181370A HUE026334T2 HU E026334 T2 HUE026334 T2 HU E026334T2 HU E12181370 A HUE12181370 A HU E12181370A HU E12181370 A HUE12181370 A HU E12181370A HU E026334 T2 HUE026334 T2 HU E026334T2
Authority
HU
Hungary
Prior art keywords
optionally substituted
aliphatic
kst
aryl
group
Prior art date
Application number
HUE12181370A
Other languages
English (en)
Inventor
Ruah Sara Hadida
Mark Miller
Jinglan Zhou
Brian Bear
Peter D J Grootenhuis
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of HUE026334T2 publication Critical patent/HUE026334T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)

Claims (7)

  1. SaafeaRakai igdßypoRtofc !. (ί) k aplati! vegybka
    vagy gyögyfeaSilag dfegaiiaté: sbja, SÜ$ dkRvaiksyÔk tmnRegyike esetés egyméstéi tSgpknôl: Ri jekfiîéss a MvAes&amp;fc acte «setfee» enèotteftil \S. ^mmrnsmm :#i|s esoporR pÄ e^stbas s2aïîss2îiiaMi: art, ado® asatbeo smbsxRöÄ haterosfik adbti ssdbas: saubsaiRiäR, 3-^10 tag« töeh3«i;MÄ «apport, aaaal a RltéteM, bogy iagaübb ogy Ri jaieabîse a kövstteök Äagpls; Ä» «sotbaa sgubsatitaatt helaroeikloalikb «sopori, ado® t^#»n smlnmmàk -mi- mgy ado» ese&amp;en saabsatitkàit baiaraari:!. ameiÿ m k#kiöö|ip gyßri IvgspöaidpSate kapcsolddik; RJalÄsa |yrpg^:aa!^ adoît gseiban saidisÂiàik 1 -δ s?ippats>«ât»# aidas csc$or§ R* ê$. 8¾ a sÂatMssîa] egylM %ggK^|Ââk,: «φ*&amp; essbxar s*#s;Ritaa?k sÂaîaâp- szàpô dkfcp impéiWi kêpa; :R!: jefafee fad, smaîÿ adöts «serbes aKabmiiaälyä vas, é» n erteke t, aläöl ax asrR ado® mstbm jelas'kvb sadfegitaeftiS^I) s követkealik b&amp;naialyiketsR aMa esbpo® jpdîddrb aikü, aSkesik vagy alkb-RR; cikioailfâs csoport; ciktealtias-aiiîâs; heîefoeikloaiifas; heterocikioal i Sas-al s Sas ; aril; fesr»i; stasR dkloablas-oxi;; keRrodkloatitis-axi; arsioxi; be&amp;mriloxs; aiaiifss-oxi; beteroaraRfeoxl; sroR; hateroaroR; arospp;: oxoesopm iQ^ssaalei koadeaaàit: Ârklasoa vagy tricikbisos aril oei« apsîgâa karboclfclissos gywdlag); pig-oepp^t; kadàsxk aroidsssoport; adl j^siddai alikiskarbonil; cikloaHiasdiaiten;: cikUraililS'ablis^afböPik arsifckarboRil; ^^tkjbaUi^-'kaælwîk: beisroetkk>aliias-aiiisHkaifeosi| vagy beRro;aafifôs-kartxiuii;5 smdlboR [pékbiul aiifâs snRfam! vagy arokxs;rrd!onR|; sxuUmii [példârd allias saalfei vagy dkloaiRis :ssärSbil|:; äkÄml fpéldâal aR% säö|lsal||; dasoesogo®; balggèm bidroxi; merkaptocsopôrt; szulfbxi; kartwod; nokarbamid; szuHknoR; sxulfanbd; vagy ksrbamoll ahoi a Rderoard adott je|®iiï§$§ a kövsfetök: alÄ. g®Sffpr|példâui alkil, alkesil, vagy aÂ% dkfeaiiax esopbrg dkäosSAvsäÄ «sgprt; ketemdRirsaRSis: asöprg ireterodklöaÄ® alibis csoporî; aril; hetemanl; aäkoxi; cikloalliäs-oxi; beferr^Moaiilbs-Pxl; ardoxi; beterganioxi; araRfäs-oxi; bdsraaraRiäxxrd; arbij RetemaadR; amis®; paoesoport (feiclklasos vagy srlcikiases boteroarii mm mimés karbocikiiasos v^y testrsciktasos gydriydaR; ksijpaR aoiidöcsopoit; acd Ipdldard alliäa-karbonR;; oikloaliRix·' karboail; cillbaliibsrabtisdiavbddk araiRis-karbasik belsroeikioalitäs-k^boml; beiarp«iklôati:fca|iils~ karboail; vagylâéieb5g|-alli;isskarbuoiî|. sxuUbml (peidkui äRilsSÄgiibPil S'agy am^össallbßji]; smd&amp;ü|pdlddtii alikissaaiinaill; saalfäali l'pdiddul aRiäss^aRaadk «Rropsppprt; clapdesopen: hslögdp; bidKsxi; înasicapto-esppörä:; sagi$5xi; kai^aaiirk uokailsaaridysaullaaroll; szulismid; vagy katbäisoil; aüôl a bbiarpeikioaidas-esopai'i adbd assRsaa jeisaldvö saafesalitoapsd a: kövatksxdk: alRSs: dsoporf IpdlRaa! All* alksol! vagy: alktadji, elkloaRills «soport cikiaailiäs-aMis esoport, haterocikioalikls osaporg RgtäröcikirxRl^s--arfe:: csopart. arR, RäSeröaril alkoxä, dkioalRts-oxî, beiemctfclosItÉSHôXg arilôkl; belbPk&amp;fck ap-dstSs-ed, ld*dx>a#lps*öx| aroil, îWssœcSi^M, astisdocsoppp: Ipskiâd $|Éâ* lääÄiiHfc^ O'-iSSö^i'i, c ik I<5«y fas - fcas^Soriiisî<ï; ésklô;stî i^ ^ii } ^s - ka^bôft:lia îTrtmô' *sopi>yi:> as#> lâÉôÉâÂw^iÊ^o«, iarabfbs4;s£bddlam!no--cspprk hdfcrudk ioaH^-kàrtÂta«KK:s^i>f% psigTßCäkloäHils^äHilsiksrbsKllsminöcsopöö, vagy lu&amp;troaralH&amp;t* käü'höäsiämfoö!,: d®x:söpork karboxl IpélÉkil: JIQÔC-* afexikarboîdl vagy alkHkarbemiokil, adl fpéldéui eskioabfe-kaitoslj ciklosbMs-£bif&amp;s-k8rbosi|: amilfckarbßd!, tosr«®teaÄ«4Kdfeonil, fc^odktoaIifös-aliils-kaÄcsIl, vagy :feei«Fö^&amp;]i1ks~karboRil;]s niroesapast, eiassoesoposri, Mlogdg Äroxi rpeikspöcsoport, sxdfippf fpÄ# ÄI!k«pi&amp;dB -vagy anlsKpJfeäsi|: sxullMI Ipdldäpf aMfcmrfimlJ, xpdl&amp;ai! jjpéld&amp;ïii alll«2ÂPÎ3|, sauii&amp;xls kapfeapxkl, bokaxb&amp;mid,, sggif»o05 asadlaxasd, oxpesspoxt vagy karbamoi;. φβ m "äliis’ kiÎsleKés ma#ba« &amp;gla|a »z alkik alkenlk alkmB kifejcxd'seket; ö!k)I sgy alklicpïpiî adoîï esetbenj«l#|lévô szubsztituense: a követkcxök. hakœàv <.aklosS:i|ls psöpori fpdSdid dklôalkü yagy eÉloslkmlj, bsteroclkloalifà» csoport lpéldât-1 hes«ocâdoa!kn vagy bderodkks-alkesil,. aril, bds«»i, alköd, atoll., betemaroO, acû jpéldâui alUäs-karhonll, cskdabiasdiarbossii vagy keletxïelkhalMsykarbodll mbocsoport, -ctoocsoport, ataidocsoport fpiilaä QÉfekW^ÂI^isÉÂîtejaô- -: export, arlikarbonilanürtö-esopo«, aralMlkarhodlaadfio-essposl, betorocikkKxIkHalkil'karKwäämlb-ö-csopoft, beior^rilka^iakmlkHsSKfiiGirt*: csopwtj, «mmoevoport jpéidé«! ailills amdoesopörk çifejbaHf&amp;s dPmpcsopori, vagy ikderaelkkayÄs ajma«ssopo!?|f s<?.altonli (pëkMïd alifässxalfoailj, saÄmi, sxylßmH, .séÂm, fe&amp;bsmkk difexbasdd, szdiSmtöll iSKulfaaikî, oxoescippsd kaxboxk karbap5pi| cikioalnas pki hetmfc&amp;toaHfisôxi* srifed, be&amp;rôadfei, andkiloxi höteroaiiälkPkijsÄoxto^kiiB^Äiarboniioxi, vsigy kkiroxil; a&amp;öil egy alkedfcaopon adPtl -esotbéa jddddvê sakhs^itueasd a kdÿptkëîiôk: Idlôgëb, dklMÎÎâs psopod:, &amp;eîeiôdkk>a3 esopori, arii, ketemarfl, alked, atroü, hetero&amp;reü, sell [péld&amp;d clkloalifés^aiIgHiii yagy lîéiSieKîkkiaiiiâs-karboRlâj,, mliracsoperî, ciaaocsep©«» acil [pétdâui alMés karkaiàk cîkimMm karbsnik ardkaibgpil* keterodkballfês kaxbodl vagy· hdsxomlkarbosbl}, amklocsoporl [pdyäbkdklo&amp;|klialkU4c<ab0^ aikmiîKî-esDpon, arfik*tbs>jääa*nsao-csoport, aralkiikaxbomkRimiix^saport, bstmÄ^I|k|l?kaitoRjfeinlatv esoport, beterocikloalkilalkH-karboailaralno-csopon, heloroarilkarbonüammo-es^îî, bdaioaraMkadippsl·' aislsö-esopöik &amp;lkHam»x>karbôt«l ciktoalkilamtnokarhonli, bdsrocikloalkitemdPkafboidl,: arilamlRokarkktaik ^gytoereadlaminokarlxsnli], amlmxsopott fpökkkd atiiks atniHOcsopö«. vag) aluas i^|önilmi:iöä«i5Si^port]{ szâl&amp;kd! Ipéldatîi alkifezulfosil clkloaUfös sxu!fi>t»k vagy arilszalfoatlj. saulfiaik sa«lt^ä% smlfoxli, ka^atatd, tiokatbamsdj .sxidAitsoil s«dSdrbd; exoosopsrt, k^rbpxk karbamod, dkl©al&amp; <m, betemcikio&amp;lllils oxi,, âî-llôxg:bsîem&amp;rikixk anàklioxg h©i8mmyki3fxi.ilökoklilii^bik. alkilkarbosiloxk vagy kkSrmiik: lakd egy alki«Hcsop<m sdmi essîbes jeïôBlëvl Ssdd5S2disaeRs«l: a kbveikoÂï s»öi!. hstas-oaioäl;,. aikoxl, clktoSdb*li'b«terocikksdklksxi, axstoxi, beîiSroarikpîk axalkiloxk kaxbexl, cianoesoport, balogdP, bkli-axL sxalfe, msrkaptoaaoport, axdtkftil Ipëlilédl: alliia: szuHatiH vagy dklöaSläs xxuife:il|, szaîSalî |pÄt«!: alÄ szallöil ¥sgy eildokK®s sxa|11:ail|s sdiällöslji |p6ldpui ab.fäs s/tdfonik a!Ä :a»l«oszaÄliy vagy plklpaMMa δχχΐΙ^ΙΙΙ, amidoesopört Ipëldâa! .dklwmokiartjodl, a|fcilkapm0:lapppocsöport? blklödlklkppäokÄöpl, î^i^kïoaMtefiïin.tteéimllj,: piklpsdkllksÂpSpîîxiiîo-espppk axdpmpäi^arbßfdl,. «r?$£!!^ bdemeikloaifcll-karbaidlamis^-esopön, plklöaSkilaikib: karbPPilamlao--espppd,. toiäöapdkikabböpüajp :bptspai|l:kajböjd;toxänö-cppört vagy ktsw«il- aHïiædkakbomlj, kartiSHild^ tiokai'baïîdd^ skdlfembl, WâW®M*· »teklk&amp;fbßtdl, alklkarfeoîidsxl, dkloaigs csopöft, heteroevkkmltfe esoport srik hetaxadi» acii fjsgy&amp;a dy@a»4ca?fe^il vagy hetemäkfealifäs-· fcöfcamH, aaHRoewport |p£k$äl ös<kisöj5«5'k kaïtxîxl k«b«àk dkksaHiaS-PÄ Md'öcikba:ifös.'CN g v&amp;gy (bdedaRÛMkôkl; ahoi egy dkteÎifôs esepod: étkiit «setfee». jefeöMvb szabs/£h',a5!%e* a kövdkpÄ: allies Cstpst IpéliMu! alkig aikeaik vagy âteli'i, cikloaüîbk csopkik «ikioalikis-aHfas cs^ô^ ldîerodsloaiîi^s csopoik kidrocÄdiiSs-alffös esopesl:. adk hdem&amp;rik ftÉëki· ÄoalÄNSxt, aräfosx, heteroadk im, araffis-axk kderoaräiäläs-'öxs, awÖ« feekireardk amdsesijpbFL amiidasssspiM JpékiâuS aSife-karixsidi--waa^sopsart* cik]oäIi&amp;~karbo5»]^yo'esopoö, cikfoaiÄ-aS&amp;-tei^tei»ß^^t«. iaakkarboailamihs-esoped, ;»alilSs-4iaÄs«feminö~esö]>Oik h^rocik^ödsfekaFbösnsiKsso^s^ösl:, hefefodktealäiis-äliäfc--karkefilkiïtHno-csiipôfk vafy S^etp^aialslas-karkossjjaisiiso-cseport], mm- •.esüpsst, k^m llili IpXKX afekikaFfeopii va$r &amp;lki!karfeoal|»?d:|, adi fpèkl^td dklo&amp;Iifâs-karboRi}, cikiôaHfôs-akfâs-kasèpp?!, afsHfa^-kartei!, hekjroeilpsisias-kykdsd, :|iKm»{kloaHfàs-aHféis-kaxÎx»{H vagy kmroai^y^Ss^as-beaö], danocsapor^ : Wôg#». jMMk R^kapSöP8öp<m, ssuHbns? [pékübd dkilszutfoas! ês softünff [péliMui aäklteg«liäpii|: sgplfegd fpdIÄ# #HmiUaailj> sauifoxk karbamid,. A-:tata»id» malJamoö, - sml&amp;jsafcl .oxpc&amp;öpott v&amp;gy karhsmösk
  2. 2. Μ l. jgäiypifd: «xsristi: vegyüieg akd sa Ixoktelfe gjföii. N* pKdeiôjéta kapcsoÄlä k,1 vagy :> -Z^R^cvoporttai van szabsdAâlva, #îôI rnpAgyïkX5 jdeaAeegymkstöl Äggedsßd! kbiës vagy adÄ esetben sxabsztituâU, «dagaab -vagy >§gÿeaes, i~6 »IM&amp; :φκν atoel s Z" legfeijsbb kèi käfböasgygbge adoti: esetbea &amp;. egyïaâsîdJ föggetkoül a következ&amp;k bànaelyisévc· vaa hejyeAsdvv: -CD-, -NRSY.O-, -SO;··, -Hli\ -SO;;NR!x vagy -NRi;SOr; raîndegyik AjeSentôse egynïMé RsggeSl&amp;dM Rï;s -OH, -NH** -di'CHjk, vagy ~N'(CH:,k es «Hndegyik R£ jefentäe «gyÄöS Mggeei Mdmgéa : vagy xdsR ssaile« szafesAtÂ, 1-¾ pänuomsz&amp;niä altfäs csoport 3:, A 2.. Igëaÿpask maàM vegyafeg àhal ax tebM&amp;Ä pPdeàdâboz kapesölbdb Rj testf» amply adötJ asstta ï vagy 2 -^Rii-esoparii&amp;i vm sæafeszdtaâlva;; Üdaïôsat »eiy adiks «seifem * »2"R>r käöpöftls! va s ÿggbszïtaalva:, vagy .feeterociktealÄ csispad, mdy adôîî •mèm. I -^Rÿ-csoponta* van sKubaztiRiàiva.
  3. 4. Az :R xgépypaM SzdlkR y8|ybM, #*ô? m i?ÄÄ gy*w ^es |>«®fei4pboz feapesskîdo Rt s ÎàRsdkezÂII Ä csopfaibôâ van kh&amp;iasaiva;
    Az !. igösypoai sastisb vegyüitek,; aboi % ésRka sxÂiMîffiài egytsö, smeiyhsi Rapsôbkfnak. 3-? szë«ô8ïsæRôè elikteakllii ssoportof: képessefe, Mlößöseß æîkiopôpbgytrSî. &amp; £· igé&amp;ÿpôîg Saatbkî vegylk-R a&amp;ai 1« a fcöveike^ö&amp;ii Μδ esogorihöi y yàiass&amp;kt esopôri:
  4. 7. Ai I. igènyp&amp;iÈ s.-K-rins vxgyiikx, amdyse.kképMs a <11.1 > képseï;
    #ô^ésïaâlag slfôgadbati) séja, afcol a kôvetesSkJeienîësâ egymsuk fôggeUeaül-R}> jelentese -2?% afeol «ώά^έ^ 2? |ei«pt|s£ egymäsbM ilîggeîileniH kütéb vagy .adott sMbsxiiMélt, elagaxé vagy egyeass. 5-S z?&amp;mii)ïmxém&amp; SSas» aboi a Z!> iegfeljehb 2 $æ£ne£p|p»:'àdoit sseibes és egymésto) blggeifen-H a kôvdke>k$k bénmkyikével vas he|y®tte»itve: -CO-. - CONR!-, ·€0:Γ.. • NRsCO:r, -O-, -NRi:CO-, -SOr, -NR’\ ~SOÎNRi;-, vagy ·· KRî:S%·; R? jsîemâie R3 OH, ·ΝΗ:ί;. -N{CH;î)j, vagy (CM>}S; R<: jeienîése bidrogési vagy ÄR sseîbfôa imtediBâlt Rt s^satexisœb aiffis ßäßpari;; Rajgfepèss H v&amp;gy 1-4 szèraborasiJrnù aHfâs osopon; R, és R’·; a saésaîoïîîïîïài egyi'ut, aîHSiybe?: kapcsolôdnak, 3-7 ÿ<'ô?!âiô;tKzâHH! cikloalifôs csoporUM képaa; R* jeleotéss .teil, amdy adotii eseiben î, 2, vagy 3 ~Ζ*£*-«$θ£ΚΚ«&amp;! « szubsztîtuâlva, aboi vâtasesayi Z: jefenîése egymésléf 1bggctk»t3 klés vagy adoît esethea szate&amp;ttiéiî, eiagaao v&amp;gy egyenes, 1-6 «Äalomsxämö alflis tes, aboi a / !egk|ebb 2 saæoegysëgô adlt eseîhsn es ogyssàstôl fbggedersül s kôveikexdvd vaa hdÿettes&amp;m·; -O-;; vagy R« jeHésa s'«îï II, aavdy îsgî. vas SBahsziRgälva, anselyek a sxstt&amp;tôôïokkas, ansdyskhea kapssoRkfeal, 4-8 iagâ;, teilUR. ïiëjs«he» Ulkst vagy aroihàs gyitrü* képezoek, atnetybee legfeljebb 2 gyürôaiom O; ét R* jeSolësv ado« csetben s>&amp;ihs/muâit i -8 &amp;zcnaïomsi^mà alitls esopon,
  5. 8. Az 1, Sgéaypiao sasjrm« vegyület, amelynek képkss a (ÎVt këples:
    vagy gydgysszaoiag eSîogadhaiô soja, ahtsi a kbvetk«2ök jelenses« «gyméstô! ftiggdlenöl: T jeierusse adoit esetben »aubsaiiilUi. 1-2 sxénatomssîâmâ aidas iànc, ahoi a sxénegysegefc mtndegylke ssloR «selbe« és egyœ&amp;stô* Iggeilesll a követkexbvel vm hdye«esjtve: ~QV:; Ry jeiesRëseMdïogëe:; R"'5 al” vagy 4W ssâœôsrilskarobov kapoastéiMk:; R*·''5 és jelestése -ZßR·?, ahoi mindsgyiik Z* jetestése agynlssel ibggeümöl kôtés vagy ado« emhm sa&amp;SÄÄ, elagaBb vagy egyeaes, 1-6 8?Âab»MZtaô ails Mae, aboi: a Zu Jegfeljehb 2 saënegysëge adett eseifee« es egyssjasidli ibggettenâl a kövsSkesaSk bânselyjMvel vao beliyettesitve: ~CO~, - CON.Rs-, -GO?-, -Ck «CO-, -SOr, -N$*\ ~SO,«k vagy •bSR'SOr·; R, jdgntése Re, -OH. -NH2. -FÎ(CiH;sk vagy kNXCH.k vagy K.&amp;! ss RÎK a*, almokkal asnelyekkea kapcsoiôdnak, 3-S-Sagô mllmt, részben îedwlea vagy aromas gyôrüi fcépeæsefc, amelybeo fegfeijebb 3 gyMstag egyasastèl ibggeileMSt a;« 0 és-MR*' alkoîta esopolbôl van ksvâlasBtva; es Rb jekatëse bMïogdsî: vagy ado« «selbe« saibrföi», I; - 8 szénatoss^àï«» alliés osoeost. 9, A 8. iglaypol sxerlsb vegySitet aboi T jeSésgëse a -CH>- és -CF;;- alkotâa esoportbél van Rsyâiassïva, vagy aboi R*5t Rdealse 3” szàmô sabaatoißböz kapcsolôdo -C’OjH, R"‘" jeleaîès« H, T jelentése ~C.Fr, és R?‘ jetealsv M„ vagy aboli Rôi jekntése 4" szârtm szënaKaribi»; kapésolèdo -C02H5 R'"'" jelmtése H, T jleoîése: -CF>-, and Rt! jeieotsse H. 1Θ. A. 8, sgèsypol sæsrltl vôgyleî, aboi R;t,5: és R!;iîi, a széaatoiaokka! együtî, amelyekhex kapcsoiôdaak. adott eselbea ssalsatilâi, 3-k-laga iliRetk #szbea itUt&amp;Ûm vagy abjsiâs gyibllt képsaoek, amelyb«« 0-2 gydrôaiom· egyroâst-ôl .fôggedeaal.ax O ës NRk klkoRa csoposlbbl van kivâlasztva. 11. A 10. sgéaypom sasrIH végySll, aboi K5·1’ és SDk 3” ës 4” sxëiÂîôôkat iartalmakô leaMl! egylt a kôvsîkeab csoporsok bânneKdke:
  6. 12. Αχ 1. igëoy|xxa saenfei vagyiitet. amelynek képiefe a (V!) képk't
    ahoi Ö je&amp;nt&amp;e -0% · €HR;r vagy -NR»-; X j« usités« 0 vagy H,H; R,0 és Rj ï ]efeaî«se; ssgymâsiôlifûggelteîiôi 1¾ vagy alkftxij vsgy il(i «gySR a kôveïfeexô c^gorM kèped:
    Tjdsx;u-se CHr, -CiV» vagy ARCbVsr; 1¾ JêÉentëse hidrog#, ailiR «sktifeft i *t saéÂô^ssÂô allfls eaeptit mgÿ adoti «soite sxafesaiiti^lî ës R:' jeiemèse B. !3. A 12. igénypofe szarimi vegyökx, ahoi R<; jektxése aiifôs esopon, ad!, mati! vagy fer.il vagy ahoi Ri; jdentése afeod. 14. A 12. igénypofii szerirti vegylfeh ako! G jelemese -GR<r. Rb jelealése meiii 4s .X jdertése RSHS vagy ahol G jlteésp Ry jdaofesr i&amp;sil, es X j&amp;ientése O, vagy ahoi G jdenîése -CHR»-.· R, jdentése fefei, es X jviettîéas H,B, vagy ahoi G jelentés« -NR<,·, ;&amp;a jdôritése H., es X jeiesiess O, vagy ahoi G jdemêse -WK,r, Rÿ jslertése metîk X jdsHlése Mp. Ro jdehtése mfeoGy 4s -Mm jdertésa H, vagy ahal G jgfemès« -Oi£R<r5 R<) jGesatéSe feml> X jdissÄ ÜÄ i.;i jsleôïése: featéAg 4s R«,: jaferfess B> vagy 4ho! G jeksilés# -R R<>^ R;i ja?«atésa hi, X jéfestése (X R., jd ssäö msimk m E ** jaldRêse Hs \S. As. 1. igétsyponi saerkai vvgyütét, melynak képteté a (Vil) hapk*
    aijel ¥ jdesisss €H vagy X. azzs! a Mtétëïtel, Fogy legaiSb ep X jaispîése kg fe ki?iékë É. i 2,3; vagy 4;: T jetestése adoit sseîhen sKubsatliu&amp;l, .1-2 sadnatomsaaiaä «Il lis Mac, ahol a tafcoaegységefc mmdagyifce adoft «selbes és egyanésié! fôggsilenül helyeftMtv's. w a t$Vg&amp;ea&amp;Vel: -CF?-; és Ri: lelestsse hidrogès. 1:6. A 15. IgésyposA axermti vegyüiel, .aboi T jelmtése -€Hr vagy -CFr, ^agy àhôl-a metaMysetü Y jdssRase N, vagy shol seï àtéks 1 » 17, A 15, ïgénypont szariai! vegyület ahol R) jetasse aikoxS yagy taexi IA, Az !.. igenyposi szmnR vegyüteg ameiy a Rëyeîtaô vegyätak Mrtay&amp;e:
  7. 9. Gyégyfessd kesxitmény, ameiy tar»te»· (i| I. ïgésypmt sæermti vegjükiet, és (») gyögyäsaadiag eîfogadfeatô hmêtïzM. 2€>. A :!9, igé-sypont szsrmiî késsàtmésy, amefy tMÇâmax® tovâfehü a k(wetke;a>k bà-meh'îkét: smàôiltikus 'hat<k®yag, broacteÂtâtor, .mtîbbtlkum, fertôaéseiep,es szçr, gyuHadâsgàtfô bKîéaayag, CFTR ssodalâtôf es tkpGlekanyag.
HUE12181370A 2007-11-16 2008-11-14 ATP-kötõ kazetta (ABC) transzporterek izokinolin modulátorai HUE026334T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98855907P 2007-11-16 2007-11-16

Publications (1)

Publication Number Publication Date
HUE026334T2 true HUE026334T2 (hu) 2016-06-28

Family

ID=40303494

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12181370A HUE026334T2 (hu) 2007-11-16 2008-11-14 ATP-kötõ kazetta (ABC) transzporterek izokinolin modulátorai

Country Status (17)

Country Link
US (4) US8507524B2 (hu)
EP (3) EP3012250B1 (hu)
JP (3) JP5646338B2 (hu)
CN (2) CN102743385B (hu)
AU (1) AU2008322616B2 (hu)
CA (1) CA2705562C (hu)
CY (1) CY1115318T1 (hu)
DK (2) DK2217572T3 (hu)
ES (3) ES2556080T3 (hu)
HK (3) HK1148006A1 (hu)
HR (2) HRP20140103T1 (hu)
HU (1) HUE026334T2 (hu)
NZ (2) NZ585980A (hu)
PL (2) PL2217572T3 (hu)
PT (2) PT2578571E (hu)
SI (2) SI2578571T1 (hu)
WO (1) WO2009064959A1 (hu)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
RU2006111093A (ru) 2003-09-06 2007-10-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы атр-связывающих кассетных транспортеров
CA2545719A1 (en) * 2003-11-14 2005-06-02 Vertex Pharmaceuticals Incorporated Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters
ES2791303T3 (es) * 2004-01-30 2020-11-03 Vertex Pharma Compuesto intermedio de moduladores de transportadores de casete de unión a ATP
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
MX341797B (es) 2004-06-24 2016-09-02 Vertex Pharmaceuticals Incorporated * Moduladores de transportadores con casete de union con atp.
WO2007021982A2 (en) 2005-08-11 2007-02-22 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP1945632B1 (en) * 2005-11-08 2013-09-18 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of atp-binding cassette transporters
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US20110064811A1 (en) 2005-12-28 2011-03-17 Patricia Hurter Solid forms of N-[2,4-BIS(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
AU2006336504C9 (en) 2005-12-28 2015-05-14 Vertex Pharmaceuticals Incorporated 1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis
ES2554353T3 (es) 2006-04-07 2015-12-18 Vertex Pharmaceuticals Incorporated Moduladores de transportadores del casete de unión a ATP
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US8563573B2 (en) * 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US7754739B2 (en) * 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8969386B2 (en) 2007-05-09 2015-03-03 Vertex Pharmaceuticals Incorporated Modulators of CFTR
EP2158183A2 (en) * 2007-05-25 2010-03-03 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
JP5389030B2 (ja) 2007-08-24 2014-01-15 バーテックス ファーマシューティカルズ インコーポレイテッド （特に）嚢胞性線維症の処置に有用なイソチアゾロピリジノン
NZ585980A (en) 2007-11-16 2012-04-27 Vertex Pharma Isoquinoline modulators of atp-binding cassette transporters
CA2706920C (en) 2007-12-07 2018-02-13 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
RS55360B1 (sr) 2007-12-07 2017-03-31 Vertex Pharma Proces za proizvodnju cikloalkilkarboksiamido-piridin benzoevih kiselina
US20100036130A1 (en) * 2007-12-07 2010-02-11 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
BRPI0820681A2 (pt) * 2007-12-07 2019-09-24 Vertex Pharma formulações de ácido 3-(6-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilperidin-2-il)benzoico
JP5523352B2 (ja) 2008-02-28 2014-06-18 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｆｔｒ修飾因子としてのへテロアリール誘導体
NZ588006A (en) 2008-03-31 2012-08-31 Vertex Pharma Pyridine derivatives as CFTR modulators, in particular N-(6-(benzylamino)-5-methylpyridin-2-yl)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamide
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
EP2349223A2 (en) 2008-09-29 2011-08-03 Vertex Pharmaceuticals Incorporated Dosage units of 3-(6-(1-(2,2-difluorobenzo [d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
UA104601C2 (uk) * 2008-10-23 2014-02-25 Вертекс Фармасьютікалз, Інкорпорейтед Модулятори регулятора трансмембранної провідності при муковісцидозі
MX2011009867A (es) 2009-03-20 2012-01-12 Vertex Pharma Proceso para producir moduladores del regulador de conductancia transmembrana de fibrosis quistica.
EP3828172A1 (en) 2009-05-01 2021-06-02 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
ES2579965T3 (es) 2010-04-07 2016-08-17 Vertex Pharmaceuticals Incorporated Las formas sólidas de 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il) Ciclopropano carboxamida)-3-metilpiridin-2-il)benzoico
BR112012026255A2 (pt) 2010-04-07 2017-03-14 Vertex Pharma composições farmacêuticas de ácido 3-(6-(1-(2-,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzóico e administração das mesmas
JP2013525371A (ja) 2010-04-22 2013-06-20 バーテックス ファーマシューティカルズ インコーポレイテッド シクロアルキルカルボキサミド−インドール化合物の製造方法
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
CA2852991C (en) 2011-11-08 2019-12-31 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
CN109966264A (zh) 2012-02-27 2019-07-05 沃泰克斯药物股份有限公司 药物组合物及其施用
US8674108B2 (en) 2012-04-20 2014-03-18 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
EP2858645A1 (en) 2012-06-08 2015-04-15 Vertex Pharmaceuticals Incorporated Pharmaceuticl compositions for the treatment of cftr -mediated disorders
CA2878057A1 (en) 2012-07-16 2014-01-23 Rossitza Gueorguieva Alargova Pharmaceutical compositions of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
ES2852377T3 (es) 2013-03-15 2021-09-13 Aerie Pharmaceuticals Inc Sales dimesilato de 4-(3-amino-1-(isoquinolin-6-ilamino)-1-oxopropan-2-il)bencilo, sus combinaciones con prostaglandinas y el uso de las mismas en el tratamiento de trastornos oculares
PT3068392T (pt) 2013-11-12 2021-05-14 Vertex Pharma Processo de preparação de composições farmacêuticas para o tratamento de doenças mediadas por condutância transmembrana da fibrose quística (cftr)
DK3424534T3 (da) 2014-04-15 2021-07-26 Vertex Pharma Farmaceutiske sammensætninger til behandling af sygdomme medieret af cystisk fibrosetransmembranledningsregulator
GB201415381D0 (en) 2014-08-29 2014-10-15 Algipharma As Inhalable powder formulations of alginate oligomers
EP3204358B1 (en) 2014-10-07 2018-09-19 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
LT3212189T (lt) 2014-10-31 2020-11-25 Abbvie Overseas S.A R.L. Pakeisti chromanai ir naudojimo būdas
BR112017010406B1 (pt) 2014-11-18 2021-03-09 Vertex Pharmaceuticals Incorporated processo de realização de teste de alta produtividade de cromatografia líquida de alta eficiência
GB201504878D0 (en) 2015-03-23 2015-05-06 Algipharma As Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion
CN105153013B (zh) * 2015-09-16 2017-12-29 苏州昊帆生物科技有限公司 6‑溴异吲哚啉‑1‑酮的合成方法
GB201517639D0 (en) 2015-10-06 2015-11-18 Algipharma As Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract
MX2019002396A (es) 2016-08-31 2019-07-08 Aerie Pharmaceuticals Inc Composiciones oftalmicas.
AU2017388300B2 (en) 2016-12-28 2022-03-31 Minoryx Therapeutics S.L. Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase
CN110506037A (zh) 2017-03-31 2019-11-26 爱瑞制药公司 芳基环丙基-氨基-异喹啉酰胺化合物
US11427563B2 (en) 2018-09-14 2022-08-30 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
CN113943229A (zh) * 2020-07-15 2022-01-18 天津师范大学 生物碱pulmonarin B的合成及在防治植物病毒和病菌病中的应用

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
TW200307539A (en) * 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
KR20050061501A (ko) 2002-09-30 2005-06-22 더 리전트 오브 더 유니버시티 오브 캘리포니아 낭종 섬유증 트랜스막 전도도 조절기 단백질 억제제 및이의 용도
WO2004080972A1 (en) 2003-03-12 2004-09-23 Vertex Pharmaceuticals Incorporated Pirazole modulators of atp-binding cassette transporters
SI2910551T1 (sl) 2003-04-11 2017-07-31 Ptc Therapeutics, Inc. Spojine 1,2,4-oksadiazol benzojske kisline in njihova uporaba za zatiranje nesmiselne ter zdravljenje bolezni
US7696244B2 (en) 2003-05-16 2010-04-13 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
WO2004111014A1 (en) 2003-06-06 2004-12-23 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
RU2006111093A (ru) 2003-09-06 2007-10-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы атр-связывающих кассетных транспортеров
ZA200603515B (en) 2003-10-08 2007-11-28 Vertex Pharma Modulators of ATP-binding cassette transporters
CA2545719A1 (en) 2003-11-14 2005-06-02 Vertex Pharmaceuticals Incorporated Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
ES2791303T3 (es) * 2004-01-30 2020-11-03 Vertex Pharma Compuesto intermedio de moduladores de transportadores de casete de unión a ATP
US7522995B2 (en) 2004-02-05 2009-04-21 Nortrup Edward H Method and system for providing travel time information
CN1960966A (zh) 2004-03-30 2007-05-09 加利福尼亚大学董事会 含酰肼cftr抑制剂化合物及其用途
CA2569402A1 (en) 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
US20140343098A1 (en) 2004-06-24 2014-11-20 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
MX341797B (es) 2004-06-24 2016-09-02 Vertex Pharmaceuticals Incorporated * Moduladores de transportadores con casete de union con atp.
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
CA2582885A1 (en) 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Compounds for nonsense suppression, use of these compounds for the manufacture of a medicament for treating somatic mutation-related diseases
JP5385605B2 (ja) 2005-03-11 2014-01-08 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｐ結合カセットトランスポーターのモジュレーター
EP1863522A4 (en) 2005-03-18 2010-11-10 Univ California CORRECTIVE TO THE PROCESSING OF MUTANT CFTR IMPACT COMPOUNDS AND ITS APPLICATIONS
DK1874306T3 (da) 2005-04-08 2012-10-01 Ptc Therapeutics Inc Sammensætninger af en oralt aktiv 1,2,4-oxadiazol til nonsens-mutationssuppressionsterapi
WO2006127588A2 (en) 2005-05-24 2006-11-30 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
WO2007021982A2 (en) 2005-08-11 2007-02-22 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
ZA200803701B (en) 2005-10-06 2009-08-26 Vertex Pharma Modulators of ATP-binding Cassette transporters
EP1945632B1 (en) 2005-11-08 2013-09-18 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of atp-binding cassette transporters
US20120232059A1 (en) 2005-11-08 2012-09-13 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette Transporters
AU2006331614A1 (en) 2005-12-24 2007-07-05 Vertex Pharmaceuticals Incorporated Quinolin- 4 - one derivatives as modulators of ABC transporters
CA2635214A1 (en) 2005-12-27 2007-07-05 Vertex Pharmaceuticals Incorporated Compounds useful in cftr assays and methods therewith
US20110064811A1 (en) 2005-12-28 2011-03-17 Patricia Hurter Solid forms of N-[2,4-BIS(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
AU2006336504C9 (en) 2005-12-28 2015-05-14 Vertex Pharmaceuticals Incorporated 1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
ES2554353T3 (es) 2006-04-07 2015-12-18 Vertex Pharmaceuticals Incorporated Moduladores de transportadores del casete de unión a ATP
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
WO2007134279A2 (en) 2006-05-12 2007-11-22 Vertex Pharmaceuticals Incorporated Compositions of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
US8969386B2 (en) 2007-05-09 2015-03-03 Vertex Pharmaceuticals Incorporated Modulators of CFTR
JP5686596B2 (ja) 2007-05-25 2015-03-18 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜貫通コンダクタンス制御因子の調節因子
US20110177999A1 (en) 2007-08-09 2011-07-21 Vertex Pharmaceuticals Incorporated Therapeutic Combinations Useful in Treating CFTR Related Diseases
JP5389030B2 (ja) 2007-08-24 2014-01-15 バーテックス ファーマシューティカルズ インコーポレイテッド （特に）嚢胞性線維症の処置に有用なイソチアゾロピリジノン
NZ583878A (en) 2007-09-14 2012-10-26 Vertex Pharma Modulators of ABC transporter and cystic fibrosis transmembrane conductance regulator (CFTR)
US8163772B2 (en) 2007-09-14 2012-04-24 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxypheny1]-1,4-dihydro-4-oxoquinoline-3-carboxamide
NZ585980A (en) 2007-11-16 2012-04-27 Vertex Pharma Isoquinoline modulators of atp-binding cassette transporters
BRPI0820681A2 (pt) 2007-12-07 2019-09-24 Vertex Pharma formulações de ácido 3-(6-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilperidin-2-il)benzoico
US20100036130A1 (en) 2007-12-07 2010-02-11 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
CA2706920C (en) 2007-12-07 2018-02-13 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
RS55360B1 (sr) 2007-12-07 2017-03-31 Vertex Pharma Proces za proizvodnju cikloalkilkarboksiamido-piridin benzoevih kiselina
ES2422741T3 (es) 2007-12-13 2013-09-13 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
JP5523352B2 (ja) 2008-02-28 2014-06-18 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｆｔｒ修飾因子としてのへテロアリール誘導体
NZ588006A (en) 2008-03-31 2012-08-31 Vertex Pharma Pyridine derivatives as CFTR modulators, in particular N-(6-(benzylamino)-5-methylpyridin-2-yl)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamide
US20100256184A1 (en) 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
CN102231990B (zh) 2008-08-13 2013-09-25 沃泰克斯药物股份有限公司 N-[2，4-双(1，1-二甲基乙基)-5-羟基苯基]-1，4-二氢-4-氧代喹啉-3-甲酰胺的药物组合物和其给药
EP2349223A2 (en) 2008-09-29 2011-08-03 Vertex Pharmaceuticals Incorporated Dosage units of 3-(6-(1-(2,2-difluorobenzo [d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
DK2358680T3 (da) 2008-10-23 2013-06-24 Vertex Pharma Faste former af n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluormethyl)phenyl)-3-oxo-5-(trifluormethyl)-1,4-dihydroquinolin-3-carboxamid
CN102227430A (zh) 2008-10-23 2011-10-26 沃泰克斯药物股份有限公司 囊性纤维化跨膜传导调节因子的调节剂
UA104601C2 (uk) 2008-10-23 2014-02-25 Вертекс Фармасьютікалз, Інкорпорейтед Модулятори регулятора трансмембранної провідності при муковісцидозі
US20110257223A1 (en) 2008-10-23 2011-10-20 Vertex Pharmaceuticals Incorporated Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
WO2010078103A1 (en) 2008-12-30 2010-07-08 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
MX2011009867A (es) 2009-03-20 2012-01-12 Vertex Pharma Proceso para producir moduladores del regulador de conductancia transmembrana de fibrosis quistica.
PL2408749T3 (pl) 2009-03-20 2018-11-30 Vertex Pharmaceuticals Incorporated Modulatory transbłonowego regulatora przewodnictwa mukowiscydozy
RU2543622C2 (ru) 2009-09-17 2015-03-10 Вертекс Фармасьютикалз Инкорпорейтед Способ получения азабициклических соединений
EP2490687A1 (en) 2009-10-22 2012-08-29 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
RU2553989C2 (ru) 2009-10-23 2015-06-20 Вертекс Фармасьютикалз Инкорпорейтед Способ получения модуляторов регулятора трансмембранной проводимости кистозного фиброза
EP2491042A1 (en) 2009-10-23 2012-08-29 Vertex Pharmaceuticals Inc. Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
EP2547658A1 (en) 2010-03-19 2013-01-23 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CA3016080C (en) 2010-03-25 2019-08-20 Vertex Pharmaceuticals Incorporated Solid forms of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
BR112012026255A2 (pt) 2010-04-07 2017-03-14 Vertex Pharma composições farmacêuticas de ácido 3-(6-(1-(2-,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzóico e administração das mesmas
ES2579965T3 (es) 2010-04-07 2016-08-17 Vertex Pharmaceuticals Incorporated Las formas sólidas de 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il) Ciclopropano carboxamida)-3-metilpiridin-2-il)benzoico
NZ603044A (en) 2010-04-22 2015-08-28 Vertex Pharma Pharmaceutical compositions comprising cftr modulators and administrations thereof
NZ603042A (en) 2010-04-22 2015-02-27 Vertex Pharma Pharmaceutical compositions comprising cftr modulators and administrations thereof
CA2796602A1 (en) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
JP2013525371A (ja) 2010-04-22 2013-06-20 バーテックス ファーマシューティカルズ インコーポレイテッド シクロアルキルカルボキサミド−インドール化合物の製造方法
AR081920A1 (es) 2010-05-20 2012-10-31 Vertex Pharma Procesos de produccion de moduladores del regulador de conductancia transmembrana de fibrosis quistica
US20110288122A1 (en) 2010-05-20 2011-11-24 Vertex Pharmaceuticals Incorporated Pharmaceutical Compositions and Administrations Thereof
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
BR112013004443A8 (pt) 2010-08-23 2018-01-02 Vertex Pharma composições farmacêuticas de (r)-1-(2,2-difluorbenzo[d] [1,3]dioxol-5-il)-n-(1-(2,3-di-hidróxipropil)-6-flúor-2-(1-hidróxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropano carboxamida e administração das mesmas
CN103153286A (zh) 2010-08-27 2013-06-12 沃泰克斯药物股份有限公司 药物组合物及其施用
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
AU2012332225A1 (en) 2011-11-02 2014-05-15 Vertex Pharmaceuticals Incorporated Use of (N- [2, 4 -bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl] - 1, 4 - dihydro - 4 - oxoquinoline - 3 - ca rboxamide) for treating CFTR mediated diseases
US20140127901A1 (en) 2012-11-08 2014-05-08 Taiwan Semiconductor Manufacturing Company, Ltd. Low-k damage free integration scheme for copper interconnects
CA2852991C (en) 2011-11-08 2019-12-31 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
RU2644723C2 (ru) 2012-01-25 2018-02-13 Вертекс Фармасьютикалз Инкорпорейтед Препараты 3-(6-(1-(2, 2-дифторбензо[d][1, 3]диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты
CN109966264A (zh) 2012-02-27 2019-07-05 沃泰克斯药物股份有限公司 药物组合物及其施用
US8674108B2 (en) 2012-04-20 2014-03-18 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
EP2858645A1 (en) 2012-06-08 2015-04-15 Vertex Pharmaceuticals Incorporated Pharmaceuticl compositions for the treatment of cftr -mediated disorders
CA2878057A1 (en) 2012-07-16 2014-01-23 Rossitza Gueorguieva Alargova Pharmaceutical compositions of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
CA2890106C (en) 2012-11-02 2022-08-02 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cftr mediated diseases
US20140221424A1 (en) 2013-01-30 2014-08-07 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for use in the treatment of cystic fibrosis
DK3424534T3 (da) 2014-04-15 2021-07-26 Vertex Pharma Farmaceutiske sammensætninger til behandling af sygdomme medieret af cystisk fibrosetransmembranledningsregulator
MA54649A (fr) 2014-10-06 2022-04-27 Vertex Pharma Modulateurs de régulateur de conductance transmembranaire de la fibrose kystique
EP3204358B1 (en) 2014-10-07 2018-09-19 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator

Also Published As

Publication number Publication date
CA2705562C (en) 2016-05-17
PT2217572E (pt) 2014-02-17
EP3012250A1 (en) 2016-04-27
ES2556080T3 (es) 2016-01-12
ES2445447T3 (es) 2014-03-03
EP2578571B1 (en) 2015-09-16
EP2217572B1 (en) 2013-11-06
PT2578571E (pt) 2015-11-30
CY1115318T1 (el) 2017-01-04
AU2008322616B2 (en) 2013-07-18
US20140206689A1 (en) 2014-07-24
HRP20140103T1 (hr) 2014-05-09
CA2705562A1 (en) 2009-05-22
AU2008322616A1 (en) 2009-05-22
EP2217572A1 (en) 2010-08-18
PL2217572T3 (pl) 2014-04-30
ES2658064T3 (es) 2018-03-08
JP2015205936A (ja) 2015-11-19
SI2578571T1 (sl) 2016-01-29
CN102743385A (zh) 2012-10-24
JP2011505338A (ja) 2011-02-24
WO2009064959A1 (en) 2009-05-22
US9522145B2 (en) 2016-12-20
US20090143381A1 (en) 2009-06-04
JP5885359B2 (ja) 2016-03-15
HK1222847A1 (zh) 2017-07-14
DK2578571T3 (en) 2015-10-05
HK1177137A1 (en) 2013-08-16
HRP20151255T1 (hr) 2015-12-18
EP2578571A1 (en) 2013-04-10
NZ585980A (en) 2012-04-27
CN102743385B (zh) 2014-09-17
PL2578571T3 (pl) 2016-03-31
DK2217572T3 (da) 2014-02-03
SI2217572T1 (sl) 2014-05-30
EP3012250B1 (en) 2017-11-08
US20130296364A1 (en) 2013-11-07
JP2014077021A (ja) 2014-05-01
NZ598941A (en) 2013-06-28
CN101952254B (zh) 2012-09-05
US9012473B2 (en) 2015-04-21
US8507524B2 (en) 2013-08-13
JP5646338B2 (ja) 2014-12-24
US8722704B2 (en) 2014-05-13
US20150190390A1 (en) 2015-07-09
CN101952254A (zh) 2011-01-19
HK1148006A1 (en) 2011-08-26

Similar Documents

Publication Publication Date Title
DK2578571T3 (en) Isoquinoline modulators of ATP binding cassette transporters
US8012999B2 (en) Modulators of CFTR
JP5941095B2 (ja) Ａｔｐ結合カセット輸送体モジュレータ
EP2789606B1 (en) Modulators of CFTR
AU2013231151B2 (en) Isoquinoline modulators of ATP-Binding Cassette transporters
AU2012201325B2 (en) Heterocyclic Modulators of ATP-Binding Cassette Transporters
AU2015203461A1 (en) Isoquinoline modulators of ATP-Binding Cassette transporters